Pfizer Profit Rises, Even as Patent Issues Loom

Aug. 2, 2011
Lipitor loses patent protection in November.

Pharmaceuticals giant Pfizer said its second-quarter profit rose 5% from a year ago to $2.6 billion, slightly beating analysts' expectations.

The company's revenues for the April-June period were $17.0 billion, down 1% from the same period last year, the New York-based company said in a quarterly earnings report.

Diluted earnings per share were 60 cents, just above the consensus analyst forecast of 59 cents.

"Our performance this quarter was in-line with our expectations," CEO Ian Read said in a statement.

Pfizer's "results were impacted by losses of exclusivity of several key products in certain geographies," Read said.

Pfizer is facing uncertainty as some of its top-selling drugs are set to lose patent protection in the near future, notably anti-cholesterol drug Lipitor, which will go off-patent in the United States in November.

The company said its emerging markets unit lost $59 million in sales as a result of several key medicines, including Lipitor and sexual-potency drug Viagra, being opened up to competition in Mexico and Brazil in 2010.

Copyright Agence France-Presse, 2011

About the Author

Agence France-Presse

Copyright Agence France-Presse, 2002-2024. AFP text, photos, graphics and logos shall not be reproduced, published, broadcast, rewritten for broadcast or publication or redistributed directly or indirectly in any medium. AFP shall not be held liable for any delays, inaccuracies, errors or omissions in any AFP content, or for any actions taken in consequence.

Sponsored Recommendations

Voice your opinion!

To join the conversation, and become an exclusive member of IndustryWeek, create an account today!